Dolby Laboratories (NYSE:DLB – Get Free Report) issued an update on its FY 2027 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 4.270-4.420 for the period, compared to the consensus estimate of 4.340. The company issued revenue guidance of $1.4 billion, compared to the consensus revenue estimate of $1.5 billion. Dolby Laboratories also updated its Q1 2027 guidance to 0.410-0.560 EPS.
Dolby Laboratories Stock Performance
NYSE DLB traded down $2.56 on Tuesday, hitting $58.60. The stock had a trading volume of 4,085,503 shares, compared to its average volume of 842,639. The firm has a 50-day moving average of $60.97 and a 200-day moving average of $59.43. Dolby Laboratories has a 52-week low of $48.26 and a 52-week high of $69.95. The company has a market capitalization of $5.49 billion, a price-to-earnings ratio of 24.94 and a beta of 0.79.
Dolby Laboratories (NYSE:DLB – Get Free Report) last released its quarterly earnings results on Tuesday, November 17th. The electronics maker reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.05. The firm had revenue of $373.54 million during the quarter, compared to analyst estimates of $372.76 million. Dolby Laboratories had a net margin of 16.70% and a return on equity of 11.08%. Dolby Laboratories has set its Q1 2027 guidance at 0.410-0.560 EPS and its FY 2027 guidance at 4.270-4.420 EPS. As a group, research analysts anticipate that Dolby Laboratories will post 3.23 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. Zacks Research raised Dolby Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday. Wall Street Zen cut shares of Dolby Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Rosenblatt Securities lowered their target price on shares of Dolby Laboratories from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Weiss Ratings upgraded shares of Dolby Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, September 9th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Dolby Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.00.
Check Out Our Latest Analysis on DLB
Insider Activity at Dolby Laboratories
In other news, CAO Ryan Nicholson sold 1,183 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $65.28, for a total value of $77,226.24. Following the completion of the sale, the chief accounting officer owned 34,453 shares of the company’s stock, valued at approximately $2,249,091.84. This represents a 3.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP John D. Couling sold 7,667 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $58.78, for a total transaction of $450,666.26. Following the completion of the sale, the senior vice president directly owned 166,803 shares of the company’s stock, valued at $9,804,680.34. This trade represents a 4.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,517 shares of company stock worth $995,963 over the last three months. Insiders own 37.93% of the company’s stock.
Key Stories Impacting Dolby Laboratories
These are some of the DLB stories that stood out recently:
- Positive Sentiment: Fiscal Q4 2026 EPS was $1.25, above the $1.20 consensus, while revenue of about $374 million slightly exceeded estimates and rose from $307 million a year earlier. Dolby Laboratories fiscal 2026 results
- Positive Sentiment: Zacks Research made small upward revisions to several 2027–2028 EPS estimates, including its FY2028 forecast to $3.40 from $3.38, though it maintained a Hold rating.
- Negative Sentiment: Rosenblatt Securities cut its price target to $80 from $85. It retained a Buy rating, so the revision was a less-bullish valuation view rather than a downgrade.
About Dolby Laboratories
Dolby Laboratories, Inc. develops audio and imaging technologies used in entertainment and consumer electronics. Its offerings include Dolby Atmos immersive audio, Dolby Vision high-dynamic-range imaging, and technologies for encoding, delivering and reproducing sound and video. The company licenses its technologies to manufacturers and content businesses across areas such as film, television, streaming, gaming and mobile devices. Dolby also supports cinema experiences through technologies and services including Dolby Cinema.
Read More
- Five stocks we like better than Dolby Laboratories
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
